Know Your Investor (April Edition): OrbiMed Advisors

Shots: An American investment firm, OrbiMed Advisor is a prominent name when it comes to healthcare investments. The company boasts a robust portfolio of more than 180 companies, including AbCellera, Acelyrin, Actus Medical, and Adaptive Biotechnologies, among others In 2023, OrbiMed invested in 38 funding rounds; 11, 6, 9 & 12 every quarter across 2023…

ByPrince GiriApril 24, 2024

TOP 20

Top 20 Biopharma Deal Terminations of 2023 Based on Total Deal Value

Shots: Sticking to M&A and licensing agreements can be really challenging, especially when dealing with stringent antitrust laws and evolving regulatory challenges. In such adverse scenarios, the rational and right step seems to be nullifying the existing deals. In 2023, the termination of the deal between Janssen and Arrowhead remained the talk of the town…

ByPrince GiriApril 18, 2024

INSIGHTS+

Disease of the Month – Duchenne Muscular Dystrophy (DMD)

Shots: The Disease of the Month report by PharmaShots aims to integrate an advanced approach to disease analysis. The report delves deep into the epidemiology, market size, disease management, available therapies, and key players involved For the April edition of the Disease of the Month report, PharmaShots brings an enlightening guide to Duchenne Muscular Dystrophy,…

BySaurabh ChaubeyApril 17, 2024

VIEWPOINTS

Expanding Services: Mo Jain Sheds Light on Sapient’s Recently Launched Discovery Proteomics Services

Shots: Following the roll-out of high throughput discovery proteomics services, Mo Jain, Founder and CEO of Sapient engages in a stimulating conversation with PharmaShots Unlike conventional mass spectrometry-based proteomics methodologies in the market, Sapient’s Discovery Proteomics Services leverage the nanoparticle enrichment technology to measure more proteins and PTMs within the plasma proteome While highlighting Sapient’s…

BySaurabh ChaubeyApril 16, 2024

TOP 20

Top 20 Biopharma Companies of 2024

Shots: Driven by innovations and propelled by the pursuit of delivering the best-in-class therapies, 2023 remained a good year for the Biopharma Industry, despite a slight revenue decline, partly due to the conclusion of the COVID-19 pandemic With a CAGR of 7.8 %, the global biopharma industry is anticipated to register a market size of…

ByPrince GiriApril 11, 2024

VIEWPOINTS

Bayer at ASCO GU: Neal Shore Speaking about Nubeqa with PharmaShots

Shots: At ASCO GU, Bayer presented new data from its Oncology portfolio. The analysis revolved around NUBEQA (darolutamide), which is currently approved in the US in combination with docetaxel for the treatment of mHSPC and nmCRPC in adults Neal Shore in conversation with PharmaShots initiated the discussion by familiarizing our audience with the ARASENS P-III…

BySaurabh ChaubeyApril 10, 2024

VIEWPOINTS

Exploring Beyond: Kari Wong Sheds Light on Metabolon’s Strategic Collaboration with SITraN

Shots: Following the strategic collaboration with the Sheffield Institute for Translational Neuroscience (SITraN), Metabolon’s scientific strategic director Kari Wong, engages in an illuminating conversation with PharmaShots The collaboration aims to enhance the understanding of ALS and motor neuron disease (MND) by integrating a comprehensive biomarker approach to provide better diagnostics and therapeutics for these challenging…

BySaurabh ChaubeyApril 8, 2024

VIEWPOINTS

Fund Secured: MediWounds’ CEO Ofer Gonen in Conversation with PharmaShots

Shots: Ofer Gonen, CEO at MediWound, in conversation with PharmaShots, sheds light on recent funding from the US Department of Defence to further develop NexoBrid for the US Army NexoBrid an FDA-approved enzymatic therapy to treat severe burns is jointly developed by Vericel and received US FDA approval in Dec’22 MediWound secured an additional $6.7M…

BySaurabh ChaubeyApril 4, 2024

INSIGHTS+

Insights+ Key Biosimilars Events of March 2024

Shots: Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency   Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and patients   During March, Sandoz received the US FDA’s approval for Wyost & Jubbonti.…

ByDipanshu DixitApril 3, 2024

VIEWPOINTS

A New Hope in Bladder Cancer Combination Therapy: PharmaShots in Conversation with Ahsan Arozullah

Shots: Transformative combination therapies add wonder to oncology therapeutics now and then. Dr. Ahsan Arozullah, in another engaging conversation with PharmaShots, talks about Padcev + Keytruda therapy for adult patients suffering from locally advanced or metastatic urothelial cancer (la/mUC) Ahsan shares insights from the P-III (EV-302) trial based on which the FDA accepted Padcev +…

BySaurabh ChaubeyApril 2, 2024

Know Your Investor (April Edition): OrbiMed Advisors

Top 20 Biopharma Deal Terminations of 2023 Based on Total Deal Value

Disease of the Month – Duchenne Muscular Dystrophy (DMD)

Expanding Services: Mo Jain Sheds Light on Sapient’s Recently Launched Discovery Proteomics Services

Top 20 Biopharma Companies of 2024

Bayer at ASCO GU: Neal Shore Speaking about Nubeqa with PharmaShots

Exploring Beyond: Kari Wong Sheds Light on Metabolon’s Strategic Collaboration with SITraN

Fund Secured: MediWounds’ CEO Ofer Gonen in Conversation with PharmaShots

Insights+ Key Biosimilars Events of March 2024

A New Hope in Bladder Cancer Combination Therapy: PharmaShots in Conversation with Ahsan Arozullah

Contact US

FOLLOW US